Other
Neoplasm by Cause
CI-CAN-00000032Explore in graph →
Non-malignant195 active trials4 approved drugs1 evidence items
- NCIt
- C27933
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000032Explore in graph →
Clinical trials
708 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098891 |
| MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
| completed |
| Phase 1 |
| 24 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jan 24, 2013 |
| clinicaltrials |
| NCT00036855 | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00363272 | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00891072 | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00118170 | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | completed | Phase 1 | 150 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00051597 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | completed | Phase 1 / Phase 2 | 70 | Seagen Inc.INDUSTRY | 1 | Oct 12, 2011 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT00001535 | Twins Study of Gene Therapy for HIV Infection | completed | Phase 1 | 48 | National Human Genome Research Institute (NHGRI)NIH | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00002136 | A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002137 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4 | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002138 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002153 | Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders | completed | Phase 1 | 25 | DEKK-TEC, Inc.INDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002262 | A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma | completed | Phase 1 | — | University of California, San FranciscoOTHER | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002342 | A Study of Tecogalan Sodium | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jan 24, 2013source: clinicaltrials